Rod Distribution and Muscle Fiber Type Modification in the Progression of Nemaline Myopathy

Abstract

Nemaline myopathy is a structural congenital myopathy associated with the presence of rodlike structures inside the muscle fibers and type I predominance. It may be caused by mutations in at least five genes: slow α-tropomyosin 3 (chromosome 1q22-23), nebulin (chromosome 2q21.1-q22), actin (chromosome 1q42), tropomyosin 2 (chromosome 9p13), and troponin T1 (chromosome 19ql3.4).The effect of these mutations in the expression of the protein and the mechanism of rod formation is still under investigation. We analyzed the possibility of progressive alterations with time and/or disease evolution, such as transformation of type I to type II fiber and rod pattern and distribution in muscle fibers from patients with nemaline myopathy, through a morphometric and immunohistochemical analysis of different muscle protein isoforms. A tendency of diffuse rods to be organized in the subsarcolemmal region was observed in two patients who were submitted to subsequent biopsies after 10 and 13 years. Additionally, we observed the expression of type II protein isoforms in type I fibers and a higher proportion of type II fibers in the younger patient of a pair of affected sibs, giving further support to the hypothesis of progressive conversion of type II to type I fibers in nemaline myopathy. (J Child Neurol 2003;18:235—240).

Get full access to this article

View all access options for this article.

References

Shy GM , Engel WK , Somers JE , Wanko T. : Nemaline myopathy. A new congenital myopathy. Brain 1963;86:793—810.

North KN , Laing NG , Wallgreen-Pettersson CJ , and the Enmc International Consortium on Nemaline Myopathy: Nemaline myopathy: Current concepts. J Med Genet 1997;34:705—713.

Wallgren-Pettersson C. , Laing NG : Report of the 70th ENMC International Workshop: Nemaline myopathy. Neuromuscul Disord 2001 ;11:589—595.

Laing NG , Wilton SD , Akkari PA , et al: A mutation in the alfa tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nat Genet 1995;9:75—79.

Tan P. , Briner J. , Boltshauser E. , et al: Homozygosity for a nonsense mutation in the α-tropomyosin gene TPM3 in a patient with severe nemaline myopathy. Neuromuscul Disord 1999;9:573—579.

Pelin K. , Hilpelä P. , Donner K. , et al: Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci U S A 1999;96:2305—2310.

Nowak KJ , Wattanasirichaigoon D. , Goebel NH , et al: Mutations in the skeletal muscle alpha actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet 1999;23:208—212.

Donner K. , Ollikaine M. , Pelin K. , et al: Mutations in the β-tropomyosin gene in rare cases of autosomal dominant nemaline myopathy. Neuromuscul Disord 2000 ;10:342—343.

Johnston JJ , Kelley RI , Crawford TO , et al: A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. Am J Hum Genet 2000;67:814—821.

10.

Dubowitz V. : Muscle Biopsy. A Practical Approach, 2nd ed. London, Balliere Tindall, 1985.

11.

Goebel HH , Fidzianska A. : Classification of congenital myopathies, in Lane RJM (ed): Handbook of Muscle Disease. New York, Marcel Dekker, 1996:165—175.

12.

Wallgreen-Pettersson C. , Rapola J. , Donner M. : Pathology of congenital nemaline myopathy. A follow-up study. J Neurol Sci 1988; 83:243—257.

13.

Wallgren-Pettersson C. , Laing NG : 40th ENMC International Workshop: Nemaline myopathy. Neuromuscul Disord 1996 ;5:389—391.

14.

Dubowitz V. : The Congenital Myopathies. Muscle Disorders in Childhood, 2nd ed. London, WB Saunders , 1995.

15.

Bottinelli R. , Reggiani C. : Human skeletal muscle fibres: Molecular and functional diversity. Prog Biophys Mol Biol 2000;73:195—-262.

16.

Beggs AH , Byers TJ , Knoll Jhm , et al: Cloning and characterization of two human skeletal muscle α-actinin genes located on chromosomes 1 and 11. J Biol Chem 1992;267:9281—9288.

17.

North KN , Beggs AH : Deficiency of a skeletal muscle isoform of αactinin (α-actinin 3) in merosin-positive congenital muscular dystrophy. Neuromuscul Disord 1996;6:229—235.

18.

Gurgel-Giannetti J. , Reed UC , Bang ML , et al: Nebulin expression in nemaline myopathy . Neuromuscul Disord 2001;11:154—162.

19.

Vainzof M. , Zubrzycka-Gaarn EE , Rapaport D. , et al: Immunofluorescence dystrophin study in Duchenne dystrophy through the concomitant use of two antibodies directed against the carboxy-terminal and the amino-terminal region of the protein. J Neurol Sci 1991;101:141—147.

20.

Werneck LC , Jamur MC , Silvado CE , et al: Miopatia nemalínica. Relato de caso com estudo histoquímico e microscopia eletrônica. Arq Neuropsiquiatr 1983;41:199—207.

21.

Akiyama C. , Nonaka I. : A follow-up study of congenital non-progressive myopathies. Brain Dev 1996; 18:404-408.

22.

Shimomura C. , Nonaka I. : Nemaline myopathy: Comparative muscle histochemistry in the severe neonatal, moderate congenital and adult-onset forms. Pediatr Neurol 1989;5:25—31.

23.

Michele DE , Albayya FP , Metzger JM : A nemaline myopathy mutation in α-tropomyosin causes defective regulation of striated muscle force production. J Clin Invest 1999;104:1575—1581.

24.

Kelly AM , Rubinstein NA : The diversity of muscle fiber types and its origin during development , in Engel GA , Franzini-Armstrong C (eds): Myology, 2nd ed. New York, McGraw-Hill, 1994, 119—133.

25.

Pons F. , Leger JO , Chevally M. , et al: Immunocytochemical analysis of heavy chains in human fetal skeletal muscles. J Neurol Sci 1986;76:151—163.

26.

Nonaka I. , Ishiura S. , Arahata K. , et al: Progression in nemaline myopathy. Acta Neuropathol 1989;78:484—491.

27.

Sewry CA : The role of immunocytochemistry in congenital myopathies. Neuromuscul Disord 1998;8:394—400.

28.

Vainzof M. , Costa CS , Moreira ES , et al: Deficiency of α-actinin 3 (ACTN3) occurs in different forms of muscular dystrophy. Neuropediatrics 1997 ; 28:1—6.

29.

North KN , Yang N. , Wattanasirichaigon D. , et al: A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet 1999;21:353—354.